Dorzolamide Hcl (Ophthalmic)

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
2
Deaths Reported
1250.0%
Death Rate

Active Ingredients

Dorzolamide Hcl (Ophthalmic)

Administration Routes

UnknownOphthalmicTopical

Species Affected

Dog 15
Unknown 1

Most Affected Breeds

Shih Tzu 5
Schnauzer - Miniature 2
Spaniel - Cocker English 1
Terrier - Boston 1
Beagle 1
Greyhound - Italian 1
Terrier - Welsh 1
Spaniel - Cocker American 1
Poodle - Miniature 1
Unknown 1

Most Reported Reactions

Decreased appetite 3
Seizure NOS 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Vestibular disorder NOS 3
Emesis 2
Hyperglycaemia 2
Behavioural disorder NOS 2
Death by euthanasia 2
Anaemia NOS 2
Thrombocytopenia 2
Neutrophilia 2
Elevated serum alkaline phosphatase (SAP) 2

Outcome Breakdown

Recovered/Normal
5 (33.3%)
Ongoing
4 (26.7%)
Outcome Unknown
3 (20.0%)
Euthanized
2 (13.3%)
Recovered with Sequela
1 (6.7%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 2
Case-fatality rate (reported events) 1250.0%
Distinct species in reports 2
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dorzolamide Hcl (Ophthalmic) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Dorzolamide Hcl (Ophthalmic), including 2 reports in which the animal died — a 1250.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dorzolamide Hcl (Ophthalmic). Reported administration routes include Unknown, Ophthalmic, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dorzolamide Hcl (Ophthalmic) reports are Dog (15 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (5), Schnauzer - Miniature (2), Spaniel - Cocker English (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dorzolamide Hcl (Ophthalmic) are Decreased appetite (3), Seizure NOS (3), Lethargy (see also Central nervous system depression in 'Neurological') (3), Vestibular disorder NOS (3). Of the 15 reports with a coded outcome, Recovered/Normal is the leading category at 33.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dorzolamide Hcl (Ophthalmic).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial